GAO: FDA Should Announce Plans to Revise Product-Specific Guidances for NBCDs in Advance

Drug Industry Daily
A A
The GAO called on the FDA to make its plans for publishing and revising guidance for nonbiological complex drugs (NBCDs) public, noting that sudden guidance changes cause a major expense for generics developers and can delay or prevent market entry of products.

To View This Article:

Login

Subscribe To Drug Industry Daily